Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine
  • CME

In this CME-certified, on-demand Webcast of a CCO symposium at SNO 2019, a panel of expert faculty reviews and discusses the latest data on the use of tyrosine kinase inhibitors for the treatment of glioblastoma.
Tom Mikkelsen, MD, FRCPC
Program Director
Manmeet S. Ahluwalia, MD, FACP
Rimas V. Lukas, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: January 17, 2020 Expiration: January 16, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate new targeted therapeutic TKIs into clinical practice for patients with glioblastoma multiforme based on individual patient and tumor characteristics
  • Describe the rationale for targeting NTRK gene fusion in glioblastoma and the effects of NTRK fusions on standard treatment selection
  • Discuss the current and emerging clinical data on promising small molecule TKI therapies for specific targets in the treatment recurrent glioblastoma multiforme
  • Select optimal treatment for patients with recurrent glioblastoma multiforme based on current evidence and molecular markers

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Tom Mikkelsen, MD, FRCPC

Medical Director, Precision Medicine Program & Clinical Trials
Henry Ford Cancer Institute
Henry Ford Health System
Detroit, Michigan

Tom Mikkelsen, MD, FRCPC, has no relevant financial relationships to disclose.


Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio

Manmeet S. Ahluwalia, MD, FACP, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Elsevier, Flatiron, Forma Therapeutics, Karyopharm, Prime Education, Tocagen, Varian Medical Systems, VBI Vaccines, and Wiley; has received funds for research support from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Incyte, Merck, Novocure, and Pharmacyclics; and has ownership interest (shareholder) from Doctible and Mimivax.
Rimas V. Lukas, MD

Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Rimas V. Lukas, MD, has disclosed that he has received consulting fees from AbbVie and Monteris and other financial or material support from Bristol-Myers Squibb.


Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with glioblastoma.


The goal of this activity is to improve participants’ competence in integrating new and emerging agents into the treatment of patients with glioblastoma.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 17, 2020, through January 16, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slides highlight the regorafenib and other multiple receptor kinase inhibitors for patients with GBM.

Manmeet S. Ahluwalia, MD, FACP Released: November 22, 2019

Downloadable slides exploring optimal clinical trial designs for small molecule and other GBM-targeted therapies.

Tom Mikkelsen, MD, FRCPC Released: November 22, 2019

Downloadable slides describing the use of targeted therapies including larotrectiniib and entrectinib for patients with GBM and NTRK fusions.

Rimas V. Lukas, MD Released: November 22, 2019

Todd M. Bauer, MD; Marcia S. Brose, MD, PhD; and George D. Demetri, MD, discuss the latest data on TRK inhibitors in solid tumors with NTRK fusions.

Todd M. Bauer, MD Marcia S. Brose, MD, PhD George D. Demetri, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 15, 2019 Expiration: July 14, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Bayer Healthcare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?